Biobanking Market Insights, Share, Growth Drivers and Forecast to 2024

Biobanks are biological repository of human samples and related data which is utilized in biological research for investigating therapeutic approaches to ameliorate various diseases. Bio-specimens are characterized to determine the features of a continuous cell line, identification of contaminants and gaining profound knowledge of the raw materials utilized in the preparation of the bio-products. The process of collection of these specimens and extraction of useful information into a repository for research purposes is known as biobanking.

Browse report sample at:

The global biobanking market is expected to witness significant growth during the forecast period (2017-2023), on account of impact of various factors such as rise in on-going genomic research of several diseases, technological advancements with respect to biobanking, funding from government and private organizations, and the growing trend of cord blood repository of new born. However, sustaining the biobanks for a long term is a major challenge faced by the biobanking market.

The biobank market witnesses several drivers for its growth during the forecast period. These include the rise in on-going genomic and proteomic research of several diseases; technological advancement with respect to biobanking processing and storage; funding from government and private organizations to investigate the therapeutic efficacy of regenerative medicines; and the increasing trend of cord blood repository of new born. Moreover, the demand for personalized medication and need to opt for cost effective drug discovery procedures are also driving the growth of the biobanking market worldwide.

The rising technological innovations in the area of cell therapy presents lucrative opportunities for the key players in the biobanking market. Additionally, the unexplored market in the Asia-Pacific region, with countries such as Japan, China, India, provide ample opportunities to the key players to increase their market size and share in biobanking industry.

Key companies operating in the global biobanking market are forming partnerships, launching products, and enhancing their product portfolio to strengthen their global presence.

Browse report at:

In July 2017, BioLife Solutions, Inc. (BioLife Solutions) announced its supply agreement with Celyad SA for the use of BioLife Solutions’ CryoStor in Natural Killer receptor based T-cell platform to target solid tumours and blood cancer. Earlier, in June 2017, BioLife Solutions announced its supply agreement with Adaptimmune Therapeutics Plc. (Adaptimmune). Under the agreement, BioLife Solutions’ CryoStor clinical grade cell freeze media is to be used in Adaptimmune's manufacturing process for its SPEAR T-cells.

Some of the major key players operating in the biobanking market include Thermo Fisher Scientific Inc., PHC Holdings Corporation (Panasonic Healthcare Holdings Co. Ltd), Qiagen N.V., Merck KGaA, Brooks Automation. Inc., Hamilton Company, Becton, Dickinson and Company, Greiner Holding AG, BioLife Solutions, Inc., Promega Corporation.

Showing 1 reaction

Please check your e-mail for a link to activate your account.
  • Vijay Mishra
    published this page in Submit Content 2019-02-12 05:15:08 -0800